The function of diet and multimodal way of life interventions in Alzheimer’s prevention and administration: a mini-review

Abstract

Alzheimer’s disease (AD) is a progressive and currently incurable neurodegenerative disorder, which is driving a paradigm shift in research focus toward preventive and disease-modifying strategies. This mini-review synthesizes current evidence on dietary and lifestyle interventions for AD prevention and management from randomized controlled trials (RCTs) and observational studies. Current findings indicate that multidomain approaches, such as the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet and the Finnish Geriatric Intervention Study (FINGER) model, which integrate nutrition, physical activity, and cognitive training, consistently demonstrate efficacy in slowing cognitive decline and reducing brain atrophy in at-risk elderly populations. The evidence for specific nutritional supplements is mixed; however, certain combinations like omega-3 fatty acids paired with carotenoids, B vitamins (folate/B12), and probiotics show promise, particularly for improving memory and reducing inflammation. Intervention outcomes are significantly influenced by genetic factors, especially the APOE4 carrier status, which modulates nutrient metabolism and amyloid response, thereby underscoring the critical need for personalized approaches. Key targeted biological pathways include oxidative stress, phospholipid metabolism, and neuro-inflammation. Despite promising data, several limitations persist, such as inconsistent results, short trial durations, and a lack of standardized protocols. Future research must prioritize long-term, genetically stratified trials alongside mechanistic studies to validate efficacy, optimize personalization, and translate findings into clinically actionable, scalable guidelines for diverse populations.

1 Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder for which no cure currently exists, thereby shifting the research emphasis toward preventive and disease-slowing strategies (1, 2). Numerous randomized managed trials (RCTs) and observational research have explored a spread of dietary and way of life interventions geared toward stopping or slowing cognitive decline. Among these, multidomain approaches have demonstrated explicit promise. For occasion, a three-year RCT evaluating the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) food regimen confirmed its potential to gradual cognitive decline and scale back mind atrophy in at-risk older adults, as assessed by a validated cognitive battery (3–5). Similarly, the two-year Finnish Geriatric Intervention Study (FINGER), a multidomain program encompassing food regimen, train, and cognitive coaching, was proven to enhance international cognition in at-risk aged, with enhanced advantages noticed in carriers of the apolipoprotein E ε4 (APOE4) allele (6–8). Subsequent analyses have additional revealed that genetic danger profiles, together with APOE4 standing, can affect responses to interventions focusing on elements akin to amyloid deposition, thereby underscoring the necessity for personalised methods (9, 10).

The proof for particular dietary dietary supplements, nevertheless, is combined. Combinations akin to omega-3 fatty acids with carotenoids and vitamin E have been related to enhancements in working reminiscence, whereas probiotics like Bifidobacterium longum and the microalgae spirulina have proven potential in decreasing irritation and enhancing cognition (11–13). Conversely, different dietary supplements, together with inosine for Parkinson’s illness and low-dose leuco-methylthioninium bis (hydromethanesulfonate) (LMTM) for AD, didn’t exhibit cognitive advantages (14, 15). Synergistic results have been noticed between folate and vitamin B12 in enhancing cognition and decreasing homocysteine ranges in people with gentle cognitive impairment (MCI) (16, 17). Additionally, compounds like genistein and betaine have proven promise within the prodromal AD stage by modulating amyloid and metabolic markers (18, 19).

Multimodal interventions that combine dietary steerage, bodily exercise, and cognitive stimulation have constantly yielded advantages. The MIND-ADmini pilot trial reported improved dietary high quality and cognitive stability in sufferers with prodromal AD (20–22). Furthermore, resistance train has been proven to protect hippocampal construction in MCI, and personalised way of life interventions have led to improved cognitive scores (23, 24). Large-scale worldwide efforts, such because the United States Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER), at the moment are adapting profitable fashions like FINGER to evaluate the efficacy of multidomain methods in additional various populations (25).

Emerging genetic and biomarker insights are constantly refining our understanding of those interventions. In notably, the APOE4 genotype has been proven to modulate nutrient metabolism and amyloid pathology, suggesting that vital nutrient-gene interactions might underlie the differential responses noticed in scientific research (26). While particular nutrient mixtures, akin to Fortasyn Connect, have proven modest cognitive advantages in prodromal AD, different trials, together with the Multidomain Alzheimer Preventive Trial (MAPT), discovered that omega-3 supplementation mixed with a multidomain intervention didn’t considerably gradual cognitive decline (27, 28). Interestingly, some interventions, like virgin coconut oil, confirmed no total profit however might support particular subgroups akin to APOE4 carriers (29). Cultural diversifications, as exemplified by research on matcha tea enhancing emotional notion and sleep in people with gentle cognitive decline, are additionally being explored (30).

In abstract, present proof helps the worth of multidomain way of life interventions and focused dietary methods, such because the MIND food regimen and omega-3 supplementation, in slowing cognitive decline. Personalizing approaches primarily based on genetic danger and baseline biomarker profiles holds promise for optimizing outcomes, although longer-term RCTs are wanted to substantiate sustained efficacy and elucidate underlying mechanisms. This mini-review goals to critically synthesize the present proof from RCTs and observational research on the efficacy of dietary and way of life interventions for stopping and managing AD. Specifically, it seeks to research the effectiveness of those particular dietary methods, together with the MIND food regimen, dietary supplements, and multimodal approaches, in slowing cognitive decline. Furthermore, it should elucidate the organic pathways concerned, look at how genetic heterogeneity, notably APOE4 service standing, influences intervention outcomes, and talk about limitations of present analysis to tell the event of future personalised prevention methods and scientific tips.

2 AD prevention through dietary supplements

Emerging evidence indicates that dietary supplements may play a role in AD prevention, although their efficacy varies considerably across interventions. To provide clarity, this evidence is organized below by supplement type.

2.1 Fatty acid supplementation

The effects of omega-3 fatty acids (DHA/EPA) have been mixed and appear highly context-dependent. One study demonstrated that a combination of omega-3 fatty acids with other nutrients; specifically, carotenoids such as lutein and meso-zeaxanthin, and vitamin E, led to improvements in working memory among older adults (11, 31). In distinction, supplementation with omega-3 fatty acids alone confirmed no total cognitive profit in sufferers identified with AD, though modest enhancements have been noticed in a subgroup of those that have been APOE4-negative (32). Multidomain trials that mixed omega-3 supplementation with way of life interventions akin to food regimen and train have yielded combined outcomes, with no important slowing of cognitive decline reported within the main analyses (33).

2.2 Vitamin supplementation

Folate and vitamin B12 supplementation have been shown to reduce homocysteine levels and improve cognitive performance in individuals with MCI, with combined administration suggesting synergistic benefits (34). Long-term β-carotene supplementation, as noticed within the Physicians’ Health Study, was related to attenuated cognitive decline, notably in verbal reminiscence. However, security issues stay necessary; high-dose vitamin E supplementation at 2000 Units per day might require monitoring for potential antagonistic results, together with bleeding danger (35).

2.2.1 Probiotic supplementation

Probiotic interventions have shown potential in modulating inflammation and cognition. The probiotic B. longum BB68S was discovered to boost cognitive operate in wholesome older adults, an impact that correlated with a rise in useful intestine micro organism (36). Other probiotic formulations have additionally been proven to cut back inflammatory markers akin to high-sensitivity C-reactive protein and oxidative stress in sufferers with mild-to-moderate AD (37, 38).

In a 12-week trial, spirulina supplementation was associated with improved Mini-Mental State Examination (MMSE) scores and reduced insulin resistance in AD patients (35, 39). While these preliminary findings are encouraging, it is very important interpret them with warning. The brief intervention interval is inadequate to guage significant long-term cognitive change, and the proposed anti-inflammatory and antioxidant mechanisms, although believable, stay speculative and should not immediately confirmed by the reported outcomes.

2.2.2 Emerging nutraceutical compounds

Several other compounds have shown promise in early-phase trials. In individuals with prodromal AD, genistein, a soy isoflavone, improved verbal memory and stabilized amyloid-β deposition in the anterior cingulate cortex, indicating potential disease-modifying effects (18). Daily consumption of matcha tea was related to improved emotional notion and sleep high quality in older adults with cognitive decline, though main cognitive endpoints remained unchanged (30, 40). The efficacy of those dietary supplements is commonly influenced by genetic elements akin to APOE4 standing and baseline biomarker profiles.

Notably, dietary supplements appear to yield greater benefits when integrated into broader dietary patterns. For instance, the MIND diet, which incorporates several nutrient-rich components, has been shown to slow cognitive decline and reduce brain atrophy in at-risk populations (3–5). In abstract, whereas mechanistic help for a lot of dietary supplements is compelling, scientific outcomes have been inconsistent. Further large-scale, long-term trials are essential to validate these findings and set up optimized dosing and personalization methods Figure 1.

3 Dietary interventions and biological pathways in AD and cognitive decline

Emerging research underscores the potential of dietary interventions to modulate key biological pathways implicated in AD progression, including oxidative stress, phospholipid metabolism, neuro-inflammation, and metabolic regulation (41). Clinical trials have reported cognitive enhancements by means of the usage of dietary dietary supplements, medical meals, and regimens involving caloric restriction. However, whereas adjustments in metabolic or oxidative stress markers are ceaselessly noticed, their direct relevance to cognitive outcomes and AD pathophysiology requires additional validation. Personalized approaches that account for genetic and metabolic variability might improve intervention efficacy, although large-scale validation stays obligatory to determine strong scientific tips. The proof is organized under in keeping with the first organic pathway or intervention sort.

3.1 Antioxidant-related interventions

Several interventions appear to exert effects through modulation of oxidative stress. A four-month supplementation with fenugreek seed extract significantly improved memory and oxidative stress markers in individuals with mild-to-moderate AD, as reflected by increased total antioxidant capacity and reduced malondialdehyde levels (42, 43). Similarly, flavanol-rich cocoa improved reminiscence operate in older adults with suboptimal diet, particularly in hippocampal-dependent duties, an impact probably linked to improved vascular operate and antioxidant exercise (44, 45). Walnut consumption has additionally been related to enhanced cognitive efficiency in wholesome older adults, although no particular advantages have been noticed in AD cohorts, and the exact antioxidant mechanisms in people stay to be absolutely elucidated (46).

3.2 Lipid metabolism and membrane-related compounds

Compounds targeting phospholipid metabolism and neuronal membrane integrity have shown promise, particularly in early disease stages. Scallop-derived plasmalogens administered to individuals with mild AD or MCI showed memory improvements in female participants and those aged under 77 years, despite no overall cognitive benefit, suggesting a potential role in membrane restoration (47). Fortasyn Connect, a multi-nutrient mix containing DHA, EPA, uridine, choline, and nutritional vitamins, slowed cognitive decline and decreased hippocampal atrophy in prodromal AD sufferers over 24 months, with results attributed to enhanced synaptic formation and membrane phospholipid synthesis (27, 48). Its medical meals counterpart, Souvenaid, improved phospholipid metabolism and dietary biomarkers in gentle AD sufferers (49). Additionally, whey protein enriched with milk fats globule membrane (MFGM), taurine, and B nutritional vitamins enhanced reminiscence and processing velocity in people with MCI after 12 months, doubtless by means of mixed results on neuronal membrane composition and homocysteine metabolism (50, 51).

The effects of omega-3 fatty acid supplementation further illustrate the complexity of targeting lipid pathways. While omega-3 supplementation was found to increase neuro-filament light chain; a biomarker of axonal injury and neurodegeneration in individuals with AD, without altering amyloid-β ranges, its cognitive advantages seem like strongly influenced by genetic background (11). Specifically, omega-3 supplementation improved cognitive outcomes in APOE4-negative people, whereas APOE4 carriers exhibited impaired transport of docosahexaenoic acid to the cerebrospinal fluid (32, 52).

3.3 Food-based and multinutrient interventions

Broader dietary patterns and multinutrient interventions may simultaneously engage multiple pathways. Supranutritional supplementation with sodium selenate elevated central nervous system selenium levels, suggesting potential benefits in AD through antioxidant and anti-protein aggregation mechanisms, though direct cognitive evidence remains preliminary (44). Long-term β-carotene supplementation, as noticed within the Physicians’ Health Study, was related to attenuated cognitive decline, notably in verbal reminiscence, probably through sustained antioxidant safety (43). Intermittent caloric restriction, studied in fashions akin to a number of sclerosis with implications for AD, was related to elevated cortical quantity and decreased neuro-inflammatory markers, suggesting metabolic and anti inflammatory results (53). Conversely, high-glycemic diets have been linked to elevated cerebral amyloid burden in cognitively regular older adults, underscoring the significance of total glycemic management in metabolic pathways related to AD (54).

3.4 Anti-neuroinflammatory interventions

Targeting neuro-inflammation represents another promising avenue. Spermidine supplementation has demonstrated efficacy in improving memory and mood in older adults with subjective cognitive decline, potentially through autophagy induction and anti-neuroinflammatory mechanisms (52). Probiotic formulations, together with B. longum, have been proven to cut back systemic inflammatory markers, although direct proof of central neuro-inflammation modulation in people stays restricted (36–38) Figure 2.

4 Limitations

This review highlights several important limitations in current research on dietary interventions for AD. First, the evidence remains inconsistent for many interventions: while some trials report cognitive benefits with Fortasyn Connect or fenugreek seed extract, others show no significant effects for the MIND diet and virgin coconut oil, raising concerns regarding reproducibility and the influence of contextual factors. Second, genetic and metabolic heterogeneity significantly affects outcomes. For instance, APOE4 carriers exhibit impaired DHA transport in response to omega-3 supplementation, and medium-chain triglycerides show benefit only in non-carriers, underscoring the need for personalized approaches that are not yet fully developed (11). Third, the shortage of long-term knowledge limits the validity of conclusions; many trials, together with these investigating Fortasyn Connect and spermidine, span 24 months or much less, which is inadequate to guage sustained efficacy or disease-modifying potential.

From a mechanistic standpoint, pathways linking dietary interventions to AD biomarkers akin to amyloid-β and tau stay poorly validated. For instance, whereas folic acid and probiotics can scale back irritation, direct proof of amyloid modulation is missing. Similarly, biomarker of axonal damage and neurodegeneration markers akin to neuro-filament mild chain correlate inconsistently with scientific outcomes (55). An absence of standardization additionally impedes progress; research differ broadly in cognitive assessments device, metrics of dietary adherence, and biomarker thresholds, complicating cross-trial comparisons. Practical boundaries, together with socioeconomic disparities in entry to specialised diets akin to plant-based protocols, together with adherence challenges in superior AD as a consequence of dysphagia or behavioral signs, stay understudied. The timing of interventions is one other unresolved difficulty; most trials concentrate on prodromal or gentle AD, leaving preventive methods for preclinical phases largely unexplored. Finally, security issues accompany high-dose dietary supplements akin to vitamin E and omega-3 fatty acids, necessitating cautious monitoring for antagonistic results together with bleeding danger (40). Although multimodal approaches combining food regimen, train, and cognitive coaching present promise, their scalability and cost-effectiveness haven’t been adequately evaluated. Together, these limitations emphasize the necessity for bigger, longer-term RCTs that undertake stratified designs primarily based on genetics and baseline biomarkers, implement standardized protocols, and incorporate real-world feasibility assessments to translate dietary methods into scientific follow.

5 Future directions

Future research should prioritize long-term, large-scale RCTs to validate the sustained efficacy of dietary interventions in AD. Extending trials such as those involving Fortasyn Connect or fenugreek seed extract beyond 24 to 36 months could clarify their disease-modifying potential and safety in diverse populations (56). Stratified trial designs that enroll contributors primarily based on APOE4 standing, baseline amyloid-β and tau biomarkers, and intestine microbiota profiles are important to determine subgroups almost definitely to profit from particular interventions (57, 58). Mechanistic research ought to elucidate nutrient-biomarker interactions, akin to how selenium or spermidine influences neuro-inflammation or whether or not probiotics modulate amyloid clearance through the gut-brain axis (59, 60).

Standardized protocols for cognitive assessments, dietary adherence monitoring, and biomarker measurement are urgently wanted. Harmonizing thresholds for oxidative stress markers together with malondialdehyde, and neuro-inflammatory indices akin to neuro-filament mild, would considerably enhance cross-trial comparability. Research must also discover earlier intervention home windows, focusing on preclinical AD or high-risk teams akin to APOE4 carriers to guage preventive potential. Trials integrating diet with way of life elements akin to train and cognitive coaching should assess scalability and cost-effectiveness, notably in low-resource settings (61). Real-world feasibility research are obligatory to handle entry boundaries and adapt interventions, akin to matcha tea or region-specific probiotics, to various cultural contexts. By integrating omics applied sciences akin to genomics and metabolomics with scientific outcomes, future research can advance personalised diet frameworks and translate preclinical insights into clinically actionable tips.

6 Conclusion

Based on the extensive evidence reviewed, dietary and lifestyle interventions demonstrate significant, though complex, potential in the prevention and management of AD. The most consistent support exists for multimodal strategies, such as those employed in the FINGER and MIND trials, which integrate dietary patterns, physical activity, and cognitive training. These approaches have been shown to slow cognitive decline and reduce brain atrophy in at-risk populations. Targeted nutritional supplementation, including omega-3 fatty acids, B vitamins for homocysteine reduction, and multi-nutrient formulations such as Fortasyn Connect, also shows efficacy, particularly in prodromal and mild AD stage.

However, results are not universally positive, and considerable heterogeneity in treatment response underscores the impact of individual factors such as genetic predisposition, biomarker profiles, and metabolic characteristics. This variability highlights the imperative for personalized nutritional approaches. Translation these findings into clinical practice remains challenging due to limitations such as insufficient long-term data, inconsistent outcomes across studies, and a lack of standardization in trial design and assessment methods. Future work should focus on long-term, stratified randomized controlled trials that account for genetic and biomarker variability, along with standardized protocols and real-world feasibility studies. Ultimately, advancing from generalized recommendations toward personalized, precision nutrition frameworks, combined with multimodal lifestyle strategies, offers the most promising path to developing effective, scalable, and culturally adaptable approaches to mitigate the global burden of AD.

References

• ZhengQWangX. Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell. (2025) 16:83–120. doi: 10.1093/procel/pwae026,

• TopolE. Predicting and preventing Alzheimer’s disease. Science. (2025) 388:eady3217. doi: 10.1126/science.ady3217,

• LiuXMorrisMCDhanaKVentrelleJJohnsonKBishopLet al. Mediterranean-DASH intervention for neurodegenerative delay (MIND) study: rationale, design and baseline characteristics of a randomized control trial of the MIND diet on cognitive decline. Contemp Clin Trials. (2021) 102:106270. doi: 10.1016/j.cct.2021.106270,

• BarnesLLDhanaKLiuXCareyVJVentrelleJJohnsonKet al. Trial of the MIND diet for prevention of cognitive decline in older persons. N Engl J Med. (2023) 389:602–11. doi: 10.1056/NEJMoa2302368,

• CherianLWangYFakudaKLeurgansSAggarwalNMorrisM. Mediterranean-dash intervention for neurodegenerative delay (MIND) diet slows cognitive decline after stroke. J Prev Alzheimers Dis. (2019) 6:267–73. doi: 10.14283/jpad.2019.28,

• RosenbergANganduTRusanenMAntikainenRBäckmanLHavulinnaSet al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial. Alzheimers Dement. (2018) 14:263–70. doi: 10.1016/j.jalz.2017.09.006,

• StephenRLiuYNganduTAntikainenRHulkkonenJKoikkalainenJet al. Brain volumes and cortical thickness on MRI in the Finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER). Alzheimers Res Ther. (2019) 11:53. doi: 10.1186/s13195-019-0506-z,

• KivipeltoMSolomonAAhtiluotoSNganduTLehtisaloJAntikainenRet al. The Finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER): study design and progress. Alzheimers Dement. (2013) 9:657–65. doi: 10.1016/j.jalz.2012.09.012,

• DiasDPortugalCCRelvasJSocodatoR. From genetics to neuroinflammation: the impact of ApoE4 on microglial function in Alzheimer’s disease. Cells. (2025) 14:243. doi: 10.3390/cells14040243,

• LiZMartensYARenYJinYSekiyaHDossSVet al. APOE genotype determines cell-type-specific pathological landscape of Alzheimer’s disease. Neuron. (2025) 113:1380–1397.e7. doi: 10.1016/j.neuron.2025.02.017,

• PowerRNolanJMPrado-CabreroARocheWCoenRPowerTet al. Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: a randomised clinical trial. Clin Nutr. (2022) 41:405–14. doi: 10.1016/j.clnu.2021.12.004,

• HuangLLiXGuoMLuWZhaoJXiaoYet al. Bifidobacterium longum supplementation prevents intestinal irritation and cognitive impairment in sleep-deprived mice by modulating clock gene expression. Food Funct. (2025) 17:1366–84. doi: 10.1039/d5fo02921j,

• TrottaTPorroCCianciulliAPanaroMA. Beneficial effects of Spirulina consumption on brain health. Nutrients. (2022) 14:676. doi: 10.3390/nu14030676,

• SchwarzschildMAAscherioACasaceliCCurhanGCFitzgeraldRKampCet al. Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial. JAMA. (2021) 326:926–39. doi: 10.1001/jama.2021.10207,

• WilcockGKGauthierSFrisoniGBJiaJHardlundJHMoebiusHJet al. Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer’s disease: cohort analysis as modified primary outcome in a phase III clinical trial. J Alzheimers Dis. (2018) 61:435–57. doi: 10.3233/JAD-170560,

• UenoAHamanoTEnomotoSShirafujiNNagataMKimuraHet al. Influences of vitamin B12 supplementation on cognition and homocysteine in patients with vitamin B12 deficiency and cognitive impairment. Nutrients. (2022) 14:1494. doi: 10.3390/nu14071494,

• HamaYHamanoTShirafujiNHayashiKUenoAEnomotoSet al. Influences of folate supplementation on homocysteine and cognition in patients with folate deficiency and cognitive impairment. Nutrients. (2020) 12:3138. doi: 10.3390/nu12103138,

• ViñaJEscuderoJBaqueroMCebriánMCarbonell-AsínsJAMuñozJEet al. Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial. Alzheimers Res Ther. (2022) 14:164. doi: 10.1186/s13195-022-01097-2,

• AlipourfardFShajieeHNazari-SerenjehFHojatiVAlirezaieM. Betaine attenuates oxidative stress and cognitive dysfunction in an amyloid β-induced rat model of Alzheimer’s disease. Res Pharm Sci. (2023) 18:270–8. doi: 10.4103/1735-5362.371583,

• SindiSThunborgCRosenbergAAndersenPAndrieuSBroersenLMet al. Multimodal preventive trial for Alzheimer’s disease: MIND-ADmini pilot trial study design and Progress. J Prev Alzheimers Dis. (2022) 9:30–9. doi: 10.14283/jpad.2022.4,

• ThunborgCWangRRosenbergASindiSAndersenPAndrieuSet al. Integrating a multimodal lifestyle intervention with medical food in prodromal Alzheimer’s disease: the MIND-AD_mini randomized managed trial. Alzheimers Res Ther. (2024) 16:118. doi: 10.1186/s13195-024-01468-x,

• LevakNLehtisaloJThunborgCWestmanEAndersenPAndrieuSet al. Nutrition guidance within a multimodal intervention improves diet quality in prodromal Alzheimer’s disease: multimodal preventive trial for Alzheimer’s disease (MIND-AD_mini). Alzheimers Res Ther. (2024) 16:147. doi: 10.1186/s13195-024-01522-8,

• HashimotoTHottaRKawashimaR. Enhanced memory and hippocampal connectivity in humans 2 days after brief resistance exercise. Brain Behav. (2024) 14:e3436. doi: 10.1002/brb3.3436,

• RibeiroICTeixeiraCVLde ResendeTJRde CamposBMSilvaGBUchidaMCet al. Resistance training protects the hippocampus and precuneus against atrophy and benefits white matter integrity in older adults with mild cognitive impairment. Geroscience. (2025) 47:5267–86. doi: 10.1007/s11357-024-01483-8,

• WhitmerRA. U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER): baseline characteristics of a trial cohort enriched for risk of cognitive decline. Alzheimers Dement. (2023) 19:e082801. doi: 10.1002/alz.082801

• YangLGMarchZMStephensonRANarayanPS. Apolipoprotein E in lipid metabolism and neurodegenerative disease. Trends Endocrinol Metab. (2023) 34:430–45. doi: 10.1016/j.tem.2023.05.002,

• Aguilar-BarberàMSoler-GirabauPTabuenca-MartínAIPrieto-Del ValL. Fortasyn connect improves neuropsychiatric symptoms in patients with mild cognitive impairment and dementia: results from a retrospective real-world study. J Alzheimers Dis. (2023) 93:621–31. doi: 10.3233/JAD-221122,

• DelrieuJVellasBGuyonnetSCantetCOvodVLiYet al. Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial. Alzheimers Res Ther. (2023) 15:183. doi: 10.1186/s13195-023-01325-3,

• FernandoMSilvaRFernandoBde SilvaAWickremasingheRDissanayakeAet al. Effect of virgin coconut oil on cognition of mild-to-moderate Alzheimer’s disease patients with APOE ε4 allele. Alzheimers Dement. (2023) 19:e075934. doi: 10.1002/alz.075934

• UchidaKMenoKKorenagaTLiuSSuzukiHBabaYet al. Effect of matcha green tea on cognitive functions and sleep quality in older adults with cognitive decline: a randomized controlled study over 12 months. PLoS One. (2024) 19:e0309287. doi: 10.1371/journal.pone.0309287,

• BanaszakMDobrzyńskaMKawkaAGórnaIWoźniakDPrzysławskiJet al. Role of omega-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic (DHA) as modulatory and anti-inflammatory agents in noncommunicable diet-related diseases – reports from the last 10 years. Clin Nutr ESPEN. (2024) 63:240–58. doi: 10.1016/j.clnesp.2024.06.053,

• KalamaraTVDodosKGeorgakopoulouVEFotakopoulosGSpandidosDAKapoukranidouD. Cognitive efficacy of omega-3 fatty acids in Alzheimer’s disease: a systematic review and meta-analysis. Biomed Rep. (2025) 22:62. doi: 10.3892/br.2025.1940,

• GiudiciKVde Souto BarretoPBeardJCantetCde Araujo CarvalhoIRollandYet al. Effect of long-term omega-3 supplementation and a lifestyle multidomain intervention on intrinsic capacity among community-dwelling older adults: secondary analysis of a randomized, placebo-controlled trial (MAPT study). Maturitas. (2020) 141:39–45. doi: 10.1016/j.maturitas.2020.06.012,

• ChenHLiuSGeBZhouDLiMLiWet al. Effects of folic acid and vitamin B12 supplementation on cognitive impairment and inflammation in patients with Alzheimer’s disease: a randomized, single-blinded, placebo-controlled trial. J Prev Alzheimers Dis. (2021) 8:249–56. doi: 10.14283/jpad.2021.22,

• TamtajiORHeidari-soureshjaniRAsemiZKouchakiE. The effects of spirulina intake on clinical and metabolic parameters in Alzheimer’s disease: a randomized, double-blind, controlled trial. Phytother Res. (2023) 37:2957–64. doi: 10.1002/ptr.7791,

• ShiSZhangQSangYGeSWangQWangRet al. Probiotic Bifidobacterium longum BB68S improves cognitive features in wholesome older adults: a randomized, double-blind, placebo-controlled trial. Nutrients. (2023) 15:51. doi: 10.3390/nu15010051,

• ZhuGZhaoJZhangHChenWWangG. Probiotics for mild cognitive impairment and Alzheimer’s disease: a systematic review and Meta-analysis. Foods. (2021) 10:1672. doi: 10.3390/foods10071672,

• KimCSChaLSimMJungSChunWYBaikHWet al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults: a randomized, double-blind, placebo-controlled, multicenter trial. J Gerontol A Biol Sci Med Sci. (2021) 76:32–40. doi: 10.1093/gerona/glaa090,

• KayeADThomassenASMashawSAMacDonaldEMWaguespackAHickeyLet al. Vitamin E (α-tocopherol): emerging clinical role and adverse risks of supplementation in adults. Cureus. (2025) 17:e78679. doi: 10.7759/cureus.78679,

• JavaidMKadhimKBawamiaBCartlidgeTFaragMAlkhalilM. Bleeding risk in patients receiving omega-3 polyunsaturated fatty acids: a systematic review and meta-analysis of randomized clinical trials. J Am Heart Assoc. (2024) 13:e032390. doi: 10.1161/JAHA.123.032390,

• LiSWeiYLiangZGuoLHaoXZhangY. Review on dietary supplements as an effective improvement of Alzheimer’s disease: focus on structures and mechanisms. Food Sci Human Wellness. (2024) 13:1787–805. doi: 10.26599/FSHW.2022.9250150

• ForoumandiEJavanRMoayedLFahimiHKheirabadiFNeamatshahiMet al. The effects of fenugreek seed extract supplementation in patients with Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial. Phytother Res. (2023) 37:285–94. doi: 10.1002/ptr.7612,

• KopecREChasmanDIOkerekeOISessoHD. Re-remembering the influence of randomized β-carotene on cognitive decline. Alzheimers Dement. (2023) 19:3718–21. doi: 10.1002/alz.13018,

• CardosoBRRobertsBRMalpasCBVivashLGencSSalingMMet al. Supranutritional sodium selenate supplementation delivers selenium to the central nervous system: results from a randomized controlled pilot trial in Alzheimer’s disease. Neurotherapeutics. (2019) 16:192–202. doi: 10.1007/s13311-018-0662-z,

• Melgar-LocatelliSMañas-PadillaMCCastro-ZavalaARiveraPDel CarmenR-DMMonjeFJet al. Diet enriched with high-phenolic cocoa potentiates hippocampal brain-derived neurotrophic factor expression and neurogenesis in healthy adult micewith subtle effects on memory. Food Funct. (2024) 15:8310–29. doi: 10.1039/D4FO01201A,

• CahoonDShertukdeSPAvendanoEETanprasertsukJScottTMJohnsonEJet al. Walnut intake, cognitive outcomes and risk factors: a systematic review and meta-analysis. Ann Med. (2021) 53:971–97. doi: 10.1080/07853890.2021.1925955,

• FujinoMFukudaJIsogaiHOgakiTMawatariSTakakiAet al. Orally administered plasmalogens alleviate negative mood states and enhance mental concentration: a randomized, double-blind, placebo-controlled trial. Front Cell Dev Biol. (2022) 10:894734. doi: 10.3389/fcell.2022.894734,

• ArrietaEBazPGarcía-RibasG. FORTCARE-MCI study protocol: evaluation of Fortasyn Connect in the management of mild cognitive impairment in primary care. Front Neurol. (2024) 15:1434210. doi: 10.3389/fneur.2024.1434210,

• BurckhardtMWatzkeSWienkeALangerGFinkA. Souvenaid for Alzheimer’s disease. Cochrane Database Syst Rev. (2020) 12:CD011679. doi: 10.1002/14651858.CD011679.pub2,

• ZhaoYLiuLMaQWangYLiXZhangXet al. Milk fat globule membrane (MFGM) phospholipid – whey protein interaction characterization and its effect on physicochemical, interfacial properties and evaluation of in vitro digestion of emulsions – inspired by the MFGM. Food Hydrocoll. (2024) 155:110173. doi: 10.1016/j.foodhyd.2024.110173

• LiFHeRYueZYiHLuLZhangLet al. Effect of a 12-mo intervention with whey protein powder on cognitive function in older adults with mild cognitive impairment: a randomized controlled trial. Am J Clin Nutr. (2025) 121:256–64. doi: 10.1016/j.ajcnut.2024.11.019,

• SchwarzCBensonGSHornNWurdackKGrittnerUSchillingRet al. Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline: a randomized clinical trial. JAMA Netw Open. (2022) 5:e2213875. doi: 10.1001/jamanetworkopen.2022.13875,

• RahmaniFGhezziLTostiVLiuJSongSKWuATet al. Twelve weeks of intermittent caloric restriction diet mitigates neuroinflammation in midlife individuals with multiple sclerosis: a pilot study with implications for prevention of Alzheimer’s disease. J Alzheimers Dis. (2023) 93:263–73. doi: 10.3233/JAD-221007,

• TaylorMKSullivanDKMorrisJKVidoniEDHoneaRAMahnkenJDet al. High glycemic diet is related to brain amyloid accumulation over one year in preclinical Alzheimer’s disease. Front Nutr. (2021) 8:741534. doi: 10.3389/fnut.2021.741534,

• KörtvelyessyPArslanBNietietJLeithnerCHühnchenPBöhmerleWet al. The expanding clinical utility of blood neurofilament light chain (bNfL): a multi-disciplinary diagnostic tool. J Neurol Sci. (2025) 478:123669. doi: 10.1016/j.jns.2025.123669,

• SoininenHSolomonAVisserPJHendrixSBBlennowKKivipeltoMet al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimers Dement. (2021) 17:29–40. doi: 10.1002/alz.12172,

• ChenYJinHChenJLiJGămanM-AZouZ. The multifaceted roles of apolipoprotein E4 in Alzheimer’s disease pathology and potential therapeutic strategies. Cell Death Discov. (2025) 11:312. doi: 10.1038/s41420-025-02600-y,

• FonsecaDCda Marques Gomes RochaIDepieri BalmantBCalladoLAguiar PrudêncioAPTepedino Martins AlvesJet al. Evaluation of gut microbiota predictive potential associated with phenotypic characteristics to identify multifactorial diseases. Gut Microbes. (2024) 16:2297815. doi: 10.1080/19490976.2023.2297815,

• YuLLiBLiNYeKXLimKXKhooALYet al. Spermidine for cognitive ageing: insights into observational and interventional studies. Gen Psychiatr. (2025) 38:e101723. doi: 10.1136/gpsych-2024-101723,

• GuJGuJYuL. Selenium and Alzheimer’s disease. Chin Chem Lett. (2025) 36:110727. doi: 10.1016/j.cclet.2024.110727

• ZhaoXHuangXCaiYCaoTWanQ. The relative effectiveness of different combination modes for exercise and cognitive training on cognitive function in people with mild cognitive impairment or Alzheimer’s disease: a network meta-analysis. Aging Ment Health. (2022) 26:2328–38. doi: 10.1080/13607863.2022.2026879,